CD40 therapy and surgery: a potential immunologic partnership.
作者信息
Byrne Katelyn T, Vonderheide Robert H
机构信息
Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
出版信息
J Immunother. 2013 Sep;36(7):359-61. doi: 10.1097/CJI.0b013e31829fb871.
Abstract
摘要
相似文献
1
CD40 therapy and surgery: a potential immunologic partnership.CD40疗法与手术：一种潜在的免疫协作关系。
J Immunother. 2013 Sep;36(7):359-61. doi: 10.1097/CJI.0b013e31829fb871.
2
Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model.激动性抗 CD40 抗体治疗在一种小鼠肿瘤模型中对术后癌症复发和转移有效。
J Immunother. 2013 Sep;36(7):365-72. doi: 10.1097/CJI.0b013e31829fb856.
3
Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.局部给予的TLR7激动剂可驱动全身抗肿瘤免疫反应，抗CD40免疫疗法可增强这种反应。
J Immunol. 2009 May 1;182(9):5217-24. doi: 10.4049/jimmunol.0803826.
4
Prolonged skin allograft survival in mice treated with Flt3-ligand-induced dendritic cells and anti-CD154 monoclonal antibody.用Flt3配体诱导的树突状细胞和抗CD154单克隆抗体处理的小鼠中皮肤同种异体移植物的长期存活
Transplant Proc. 1999 Feb-Mar;31(1-2):884-5. doi: 10.1016/s0041-1345(98)01817-x.
5
CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants.CD40激活的B细胞表达完整的淋巴结归巢三联体并诱导T细胞趋化：作为细胞佐剂的潜力。
Blood. 2006 Apr 1;107(7):2786-9. doi: 10.1182/blood-2004-01-0113. Epub 2005 Dec 15.
6
Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.激动型 CD40 抗体通过抑制性 Fcγ 受体结合发挥佐剂和抗肿瘤活性。
Science. 2011 Aug 19;333(6045):1030-4. doi: 10.1126/science.1206954.
7
CD40 Agonist Antibodies in Cancer Immunotherapy.CD40 激动剂抗体在癌症免疫治疗中的应用。
Annu Rev Med. 2020 Jan 27;71:47-58. doi: 10.1146/annurev-med-062518-045435. Epub 2019 Aug 14.
8
T-cell-independent antitumor effects of CD40 ligation.CD40 配体的 T 细胞非依赖性抗肿瘤作用。
Int Rev Immunol. 2012 Aug;31(4):267-78. doi: 10.3109/08830185.2012.698337.
9
Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy.部分而非完全的肿瘤减瘤手术与化疗及辅助免疫治疗联合应用时可促进保护性抗肿瘤记忆。
Cancer Res. 2005 Sep 1;65(17):7580-4. doi: 10.1158/0008-5472.CAN-05-0328.
10
Antibodies against cell surface antigens as very potent immunological adjuvants.
Vaccine. 2006 Apr 12;24 Suppl 2:S2-20-1. doi: 10.1016/j.vaccine.2005.01.105.
引用本文的文献
1
Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy.针对胰腺癌的靶向纳米颗粒：治疗中副作用更少
Life (Basel). 2021 Nov 5;11(11):1187. doi: 10.3390/life11111187.
2
Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment.胰腺癌的新型联合免疫疗法：CD40激动剂与白细胞介素-15治疗具有强大的抗肿瘤作用
Clin Transl Immunology. 2020 Aug 15;9(8):e1165. doi: 10.1002/cti2.1165. eCollection 2020.
3
Emerging trends in the immunotherapy of pancreatic cancer.胰腺癌免疫治疗的新趋势。
Cancer Lett. 2018 Mar 28;417:35-46. doi: 10.1016/j.canlet.2017.12.012. Epub 2017 Dec 12.
4
β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8 T Cells and Undermines Checkpoint Inhibitor Therapy.在标准温度饲养的小鼠中，β-肾上腺素能信号传导抑制CD8 T细胞中的效应表型并削弱检查点抑制剂疗法。
Cancer Res. 2017 Oct 15;77(20):5639-5651. doi: 10.1158/0008-5472.CAN-17-0546. Epub 2017 Aug 17.
本文引用的文献
1
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.CD40激动剂抗体CP-870,893联合卡铂和紫杉醇治疗晚期实体瘤患者的I期研究。
Oncoimmunology. 2013 Jan 1;2(1):e23033. doi: 10.4161/onci.23033.
2
Agonistic CD40 antibodies and cancer therapy.激动性 CD40 抗体与癌症疗法。
Clin Cancer Res. 2013 Mar 1;19(5):1035-43. doi: 10.1158/1078-0432.CCR-12-2064.
3
Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations.辐照后的淋巴瘤细胞的免疫原性通过佐剂免疫治疗和局部巨噬细胞群体的调节得到增强。
Leuk Lymphoma. 2013 Sep;54(9):2008-15. doi: 10.3109/10428194.2013.769219. Epub 2013 Feb 18.
4
Cancer immunoediting by the innate immune system in the absence of adaptive immunity.先天免疫系统在缺乏适应性免疫的情况下对癌症进行免疫编辑。
J Exp Med. 2012 Sep 24;209(10):1869-82. doi: 10.1084/jem.20112738. Epub 2012 Aug 27.
5
T-cell-independent antitumor effects of CD40 ligation.CD40 配体的 T 细胞非依赖性抗肿瘤作用。
Int Rev Immunol. 2012 Aug;31(4):267-78. doi: 10.3109/08830185.2012.698337.
6
The use of agonistic anti-CD40 therapy in treatments for cancer.激动型抗 CD40 疗法在癌症治疗中的应用。
Int Rev Immunol. 2012 Aug;31(4):246-66. doi: 10.3109/08830185.2012.698338.
7
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.抗 PD-L1 抗体在晚期癌症患者中的安全性和活性。
N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.
8
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.抗 PD-1 抗体在癌症中的安全性、活性和免疫相关性。
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
9
Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.肿瘤内白细胞介素 2/激动剂 CD40 抗体驱动经治疗肿瘤的 CD4+ 非依赖性消退和 CD4+ 依赖性全身和记忆应答。
Cancer Immunol Immunother. 2012 Apr;61(4):549-60. doi: 10.1007/s00262-011-1120-5. Epub 2011 Oct 15.
10
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.CD40 激动剂可改变肿瘤基质，并在小鼠和人类中显示出对胰腺癌的疗效。
Science. 2011 Mar 25;331(6024):1612-6. doi: 10.1126/science.1198443.
Zotero 插件